Peptide length extension skews the minor HA-1 antigen presentation toward activated dendritic cells but reduces its presentation efficiency

Journal of Immunology

Volumn 185, Issue 8, 2010, Pages 4582-4589

  Hambach, Lothar ^a   Aghai, Zohara ^a   Pool, Jos ^a   Kröger, Nicolaus ^b   Goulmy, Els ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HA 1 VACCINE; PEPTIDE VACCINE; UNCLASSIFIED DRUG; HA 1 ANTIGEN; HA-1 ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; OLIGOPEPTIDE; PEPTIDE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HEMATOPOIESIS; HEMATOPOIETIC CELL; HISTOCOMPATIBILITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOID CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; T LYMPHOCYTE; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CHEMISTRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HUMANS; LYMPHOCYTE ACTIVATION; MINOR HISTOCOMPATIBILITY ANTIGENS; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 78049511274     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000213     Document Type: Article

References (44)

1. Hambach, L., and E. Goulmy. 2005. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Curr. Opin. Immunol. 17:202-210.
2. de Bueger, M., A. Bakker, J. J. Van Rood, F. Van der Woude, and E. Goulmy. 1992. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J. Immunol. 149:1788-1794.
3. Dickinson, A. M., X. N. Wang, L. Sviland, F. A. Vyth-Dreese, G. H. Jackson, T. N. Schumacher, J. B. Haanen, T. Mutis, and E. Goulmy. 2002. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat. Med. 8:410-414.
4. Klein, C. A., M. Wilke, J. Pool, C. Vermeulen, E. Blokland, E. Burghart, S. Krostina, N. Wendler, B. Passlick, G. Riethmüeller, and E. Goulmy. 2002. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. J. Exp. Med. 196:359-368.
5. Marijt, W. A., M. H. Heemskerk, F. M. Kloosterboer, E. Goulmy, M. G. Kester, M. A. van der Hoorn, S. A. van Luxemburg-Heys, M. Hoogeboom, T. Mutis, J. W. Drijfhout, et al. 2003. Hematopoiesis-restricted minor histocompatibility antigens HA-1-or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl. Acad. Sci. USA 100:2742-2747.
6. Hambach, L., B. A. Nijmeijer, Z. Aghai, M. L. Schie, M. H. Wauben, J. H. Falkenburg, and E. Goulmy. 2006. Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. Leukemia 20:371-374.
7. Hambach, L., M. Vermeij, A. Buser, Z. Aghai, T. van der Kwast, and E. Goulmy. 2008. Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors. Blood 112:1844-1852.
8. Mutis, T., R. Verdijk, E. Schrama, B. Esendam, A. Brand, and E. Goulmy. 1999. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 93:2336-2341.
9. den Haan, J. M., L. M. Meadows, W. Wang, J. Pool, E. Blokland, T. L. Bishop, C. Reinhardus, J. Shabanowitz, R. Offringa, D. F. Hunt, et al. 1998. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acidpolymorphism. Science 279:1054-1057.
10. Mommaas, B., J. Kamp, J. W. Drijfhout, N. Beekman, F. Ossendorp, P. Van Veelen, J. Den Haan, E. Goulmy, and T. Mutis. 2002. Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. J. Immunol. 169:3131-3136.
11. Speiser, D. E., D. Liénard, N. Rufer, V. Rubio-Godoy, D. Rimoldi, F. Lejeune, A. M. Krieg, J. C. Cerottini, and P. Romero. 2005. Rapid and strong human CD8 + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115:739-746.
12. Slingluff, C. L., Jr., G. R. Petroni, G. V. Yamshchikov, D. L. Barnd, S. Eastham, H. Galavotti, J. W. Patterson, D. H. Deacon, S. Hibbitts, D. Teates, et al. 2003. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 21:4016-4026.
13. Toes, R. E., R. Offringa, R. J. Blom, C. J. Melief, and W. M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93:7855-7860.
14. Toes, R. E., R. J. Blom, R. Offringa, W. M. Kast, and C. J. Melief. 1996. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumorspecific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156:3911-3918.
15. Toes, R. E., E. I. van der Voort, S. P. Schoenberger, J. W. Drijfhout, L. van Bloois, G. Storm, W. M. Kast, R. Offringa, and C. J. Melief. 1998. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160:4449-4456.
16. Bijker, M. S., S. J. van den Eeden, K. L. Franken, C. J. Melief, S. H. van der Burg, and R. Offringa. 2008. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol. 38:1033-1042.
17. Bijker, M. S., S. J. van den Eeden, K. L. Franken, C. J. Melief, R. Offringa, and S. H. van der Burg. 2007. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J. Immunol. 179:5033-5040.
18. Wilke, M., J. Pool, J. M. den Haan, and E. Goulmy. 1998. Genomic identification of the minor histocompatibility antigen HA-1 locus by allele-specific PCR. Tissue Antigens 52:312-317.
19. Gillespie, G., T. Mutis, E. Schrama, J. Kamp, B. Esendam, J. F. Falkenburg, E. Goulmy, and P. Moss. 2000. HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand. Hematol. J. 1:403-410.
20. Oosten, L. E., D. Koppers-Lalic, E. Blokland, A. Mulder, M. E. Ressing, T. Mutis, A. G. van Halteren, E. J. Wiertz, and E. Goulmy. 2007. TAP-inhibiting proteins US6, ICP47 and UL49.5 differentially affect minor and major histocompatibility antigen-specific recognition by cytotoxic T lymphocytes. Int. Immunol. 19:1115-1122.
21. Zwaveling, S., S. C. Ferreira Mota, J. Nouta, M. Johnson, G. B. Lipford, R. Offringa, S. H. van der Burg, and C. J. Melief. 2002. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169:350-358.
22. Kenter, G. G., M. J. Welters, A. R. Valentijn, M. J. Lowik, D. M. Berends-van der Meer, A. P. Vloon, F. Essahsah, L. M. Fathers, R. Offringa, J. W. Drijfhout, et al. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361:1838-1847.
23. Speetjens, F. M., P. J. Kuppen, M. J. Welters, F. Essahsah, A. M. Voet van den Brink, M. G. Lantrua, A. R. Valentijn, J. Oostendorp, L. M. Fathers, H. W. Nijman, et al. 2009. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin. Cancer Res. 15:1086-1095.
24. Gnjatic, S., D. Atanackovic, M. Matsuo, E. Jäger, S. Y. Lee, D. Valmori, Y. T. Chen, G. Ritter, A. Knuth, and L. J. Old. 2003. Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. J. Immunol. 170:1191-1196.
25. Faure, F., A. Mantegazza, C. Sadaka, C. Sedlik, F. Jotereau, and S. Amigorena. 2009. Long-lasting cross-presentation of tumor antigen in human DC. Eur. J. Immunol. 39:380-390.
26. Grommé, M., and J. Neefjes. 2002. Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol. Immunol. 39:181-202.
27. Rock, K. L., and L. Shen. 2005. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol. Rev. 207:166-183.
28. Johnstone, C., and M. Del Val. 2007. Traffic of proteins and peptides across membranes for immunosurveillance by CD8 (+) T lymphocytes: a topological challenge. Traffic 8:1486-1494.
29. Delamarre, L., H. Holcombe, and I. Mellman. 2003. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J. Exp. Med. 198:111-122.
30. Melief, C. J., and S. H. van der Burg. 2008. Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8:351-360.
31. Xiang, S. D., A. Scholzen, G. Minigo, C. David, V. Apostolopoulos, P. L. Mottram, and M. Plebanski. 2006. Pathogen recognition and development of particulate vaccines: does size matter? Methods 40:1-9.
32. Datta, S. K., V. Redecke, K. R. Prilliman, K. Takabayashi, M. Corr, T. Tallant, J. DiDonato, R. Dziarski, S. Akira, S. P. Schoenberger, and E. Raz. 2003. A subset of Toll-like receptor ligands induces cross-presentation by bone marrowderived dendritic cells. J. Immunol. 170:4102-4110.
33. Spierings, E., S. Gras, J. B. Reiser, B. Mommaas, M. Almekinders, M. G. Kester, A. Chouquet, M. Le Gorrec, J. W. Drijfhout, F. Ossendorp, et al. 2009. Steric hindrance and fast dissociation explain the lack of immunogenicity of the minor histocompatibility HA-1Arg Null allele. J. Immunol. 182:4809-4816.
34. Nicholls, S., K. P. Piper, F. Mohammed, T. R. Dafforn, S. Tenzer, M. Salim, P. Mahendra, C. Craddock, P. van Endert, H. Schild, et al. 2009. Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition. Proc. Natl. Acad. Sci. U. S. A 106:3889-3894.
35. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanomareactive CTL with peptides from the melanoma antigen gp100 modified at HLA-Ap0201-binding residues. J. Immunol. 157:2539-2548.
36. Valmori, D., J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Liénard, D. Rimoldi, V. Jongeneel, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160:1750-1758.
37. Khan, S., M. S. Bijker, J. J. Weterings, H. J. Tanke, G. J. Adema, T. van Hall, J. W. Drijfhout, C. J. Melief, H. S. Overkleeft, G. A. van der Marel, et al. 2007. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem. 282:21145-21159.
38. van Montfoort, N., M. G. Camps, S. Khan, D. V. Filippov, J. J. Weterings, J. M. Griffith, H. J. Geuze, T. van Hall, J. S. Verbeek, C. J. Melief, and F. Ossendorp. 2009. Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc. Natl. Acad. Sci. U. S. A 106:6730-6735.
39. Verdijk, R. M., A. Kloosterman, J. Pool, M. van de Keur, A. M. Naipal, A. G. van Halteren, A. Brand, T. Mutis, and E. Goulmy. 2004. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood 103:1961-1964.
40. van Halteren, A. G., E. Jankowska-Gan, A. Joosten, E. Blokland, J. Pool, A. Brand, W. J. Burlingham, and E. Goulmy. 2009. Naturally acquired tolerance and sensitization to minor histocompatibility antigens in healthy family members. Blood 114:2263-2272.
41. Verdijk, R. M., T. Mutis, M. Wilke, J. Pool, E. Schrama, A. Brand, and E. Goulmy. 2002. Exclusive TCRVbeta chain usage of ex vivo generated minor Histocompatibility antigen HA-1 specific cytotoxic T cells: implications for monitoring of immunotherapy of leukemia by TCRBV spectratyping. Hematol. J. 3:271-275.
42. *0201-restricted cytotoxic T-cell clones. Blood 85:2478-2481.
43. Haniffa, M., F. Ginhoux, X. N. Wang, V. Bigley, M. Abel, I. Dimmick, S. Bullock, M. Grisotto, T. Booth, P. Taub, et al. 2009. Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation. J. Exp. Med. 206:371-385.
44. Baron, F., and B. M. Sandmaier. 2006. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 20:1690-1700. (Pubitemid 44590958)